NCT00646165

Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia

Phase 1, Multicentre, Open-label, Dose Finding Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Mundipharma Research Limited · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To determine the dose and duration of treatment for the best overall response with Forodesine in relapsed B-cell chronic lymphocytic leukemia

Detailed description

An open label, multi centre, three arm, dose finding Phase 1 trial with Forodesine as a single drug treatment in patients with relapsed CLL to establish dose and duration of treatment resulting in the best achievable response with Forodesine as a single drug treatment.

Conditions

• B-cell Chronic Lymphocytic Leukemia

Interventions

Type	Name	Description
DRUG	Forodesine

Timeline

• Start date: 2008-07-01
• Primary completion: 2009-01-01
• Completion: 2009-05-01
• First posted: 2008-03-28
• Last updated: 2010-03-31

Locations

1 site across 1 country: Spain